These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 19858063)

  • 1. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
    Rodbard HW; Jellinger PS; Davidson JA; Einhorn D; Garber AJ; Grunberger G; Handelsman Y; Horton ES; Lebovitz H; Levy P; Moghissi ES; Schwartz SS
    Endocr Pract; 2009; 15(6):540-59. PubMed ID: 19858063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comments on the AACE/ACE statement on glycemic control for patients with type 2 diabetes mellitus.
    Eledrisi M
    Endocr Pract; 2010; 16(1):130-1; author reply 131-2. PubMed ID: 20146995
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating treatment algorithms for the management of patients with type 2 diabetes mellitus: a perspective on the definition of treatment success.
    Aguilar RB
    Clin Ther; 2011 Apr; 33(4):408-24. PubMed ID: 21635988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic control parameters in insulin-naïve patients with uncontrolled type 2 diabetes referred to endocrinologists, and degree of implementation of the national Spanish consensus for the management of hyperglycemia.
    Azriel S; Casal F; Dalama B; Varillas F; Villarroel Á; Soto A; Barberá G
    Endocrinol Nutr; 2014 Dec; 61(10):541-7. PubMed ID: 25260336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing current diagnostic criteria and treatment algorithms for managing type 2 diabetes mellitus.
    Kruger DF; Boucher JL; Banerji MA
    Postgrad Med; 2011 Jul; 123(4):54-62. PubMed ID: 21680989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liberating A1C goals in older adults may not protect against the risk of hypoglycemia.
    Munshi MN; Slyne C; Segal AR; Saul N; Lyons C; Weinger K
    J Diabetes Complications; 2017 Jul; 31(7):1197-1199. PubMed ID: 28343792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS.
    Grunberger G; Handelsman Y; Bloomgarden ZT; Fonseca VA; Garber AJ; Haas RA; Roberts VL; Umpierrez GE
    Endocr Pract; 2018 Mar; 24(3):302-308. PubMed ID: 29547046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes.
    Anjana RM; Kesavadev J; Neeta D; Tiwaskar M; Pradeepa R; Jebarani S; Thangamani S; Sastry NG; Brijendra Kumar S; Ramu M; Gupta PPK; Vignesh J; Chandru S; Kayalvizhi S; Jagdish PS; Uthra SCB; Lovelena M; Jyoti S; Suguna Priya S; Kannan A; Mohan V; Unnikrishnan R
    Diabetes Technol Ther; 2017 Sep; 19(9):533-540. PubMed ID: 28930495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P; Sugimoto D; Vlajnic A; Kilo C
    J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes mellitus: managing hemoglobin A(1c) and beyond.
    Fowler GC; Vasudevan DA
    South Med J; 2010 Sep; 103(9):911-6. PubMed ID: 20689486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring.
    Grunberger G; Bailey T; Camacho PM; Einhorn D; Garber AJ; Handelsman Y; Harrell RM; Lando HM; Law B; Leffert JD; Orzeck EA;
    Endocr Pract; 2015 May; 21(5):522-33. PubMed ID: 25962091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs.
    LaSalle JR
    Postgrad Med; 2010 Jan; 122(1):144-52. PubMed ID: 20107298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
    Nathan DM; Buse JB; Davidson MB; Ferrannini E; Holman RR; Sherwin R; Zinman B; ;
    Diabetes Care; 2009 Jan; 32(1):193-203. PubMed ID: 18945920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
    Meneghini LF; Traylor L; Schwartz SL
    Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study.
    Fu H; Curtis BH; Schuster DP; Festa A; Kendall DM
    Diabetes Technol Ther; 2014 Dec; 16(12):833-9. PubMed ID: 25068375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.
    Kennedy L; Herman WH; Strange P; Harris A;
    Diabetes Care; 2006 Jan; 29(1):1-8. PubMed ID: 16373887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.